ZW220
Advanced solid tumors
PreclinicalActive
Key Facts
About Zymeworks
Zymeworks Inc. is a global biotechnology company committed to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Its core expertise lies in protein engineering, with platforms like Azymetric™ for bispecific antibodies and ZymeLink™ for antibody-drug conjugates enabling a robust pipeline of oncology candidates. The company leverages a dual strategy of advancing its own clinical programs, such as zanidatamab, while entering into significant collaborations with major pharmaceutical firms to broaden the impact of its technology.
View full company profileTherapeutic Areas
Other Advanced solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1701 | Jiangsu Hengrui Medicine | Phase 1 |
| BAY 1895344 | Bayer | Phase 1 |
| HS-10342 | Hansoh Pharma | Phase 1/2 |
| ANKTIVA® + M-ceNK | ImmunityBio | Phase 1 |
| DFTX-101 | Definium Therapeutics | Phase 1/2 |
| REC-617 | Recursion Pharmaceuticals | Phase 1/2 |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| IMA402 (TCR Bispecific) | Immatics | Phase 1 |
| IMA403 (TCR Bispecific) | Immatics | Pre-clinical |
| BCA101 | Bicara Therapeutics | Phase 1 |
| AN4005 | Adlai Nortye | Preclinical |
| AN3025 | Adlai Nortye | Preclinical |